Buspirone for the treatment of anxiety-related symptoms in Angelman syndrome: a case series.
Psychiatr Genet
; 29(2): 51-56, 2019 04.
Article
em En
| MEDLINE
| ID: mdl-30681431
ABSTRACT
OBJECTIVES:
Angelman syndrome (AS) is a neurogenetic disorder associated with impaired expression of the ubiquitin-protein ligase E3A gene on chromosome 15. AS results in intellectual disability with limited expressive language, epilepsy, ataxia, sleep impairment, and problematic behavior which may include anxiety. Buspirone is a serotonin (5-HT)1A receptor partial agonist used in the treatment of anxiety disorders and may, therefore, have a treatment role for patients with AS.METHODS:
We describe three patients who were given open-label buspirone for the treatment of behaviors thought to be related to anxiety.RESULTS:
We found significant improvement in symptoms of anxiety with buspirone. Patients tolerated long-term usage of the medication.CONCLUSION:
The findings of this study suggest that buspirone may be effective for the amelioration of behaviors related to anxiety in patients with AS, and well tolerated. Limitations include the open-label nature of these treatments, the small sample size and the absence of a control group.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Ansiedade
/
Buspirona
/
Síndrome de Angelman
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article